Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1959 2
1961 1
1962 2
1967 1
1972 1
1979 1
1984 1
1985 1
1987 1
1988 3
1989 4
1990 3
1991 3
1992 2
1993 2
1994 3
1995 5
1996 7
1997 3
1998 4
1999 5
2000 5
2001 9
2002 5
2003 10
2004 13
2005 10
2006 15
2007 8
2008 7
2009 12
2010 9
2011 8
2012 14
2013 14
2014 11
2015 17
2016 26
2017 13
2018 19
2019 13
2020 22
2021 12
2022 18
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Results by year

Filters applied: . Clear all
Page 1
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Riaz N, et al. Among authors: gajewski tf. Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12. Cell. 2017. PMID: 29033130 Free PMC article.
CXCL9 and CXCL10 bring the heat to tumors.
Reschke R, Gajewski TF. Reschke R, et al. Among authors: gajewski tf. Sci Immunol. 2022 Jul 22;7(73):eabq6509. doi: 10.1126/sciimmunol.abq6509. Epub 2022 Jul 22. Sci Immunol. 2022. PMID: 35867802 Review.
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Peng W, et al. Among authors: gajewski tf. Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8. Cancer Discov. 2016. PMID: 26645196 Free PMC article.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Chesney JA, et al. Among authors: gajewski tf. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. J Clin Oncol. 2023. PMID: 35998300 Free PMC article. Clinical Trial.
332 results